These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 39201765)
1. Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an In Vitro Model. Galla R; Mulè S; Ferrari S; Grigolon C; Molinari C; Uberti F Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201765 [TBL] [Abstract][Full Text] [Related]
2. Design of Mixed Medicinal Plants, Rich in Polyphenols, Vitamins B, and Palmitoylethanolamide-Based Supplement to Help Reduce Nerve Pain: A Preclinical Study. Mulè S; Rosso G; Botta M; Brovero A; Ferrari S; Galla R; Molinari C; Uberti F Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732008 [TBL] [Abstract][Full Text] [Related]
3. A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator. Manzo E; Schiano Moriello A; Tinto F; Verde R; Allarà M; De Petrocellis L; Pagano E; Izzo AA; Di Marzo V; Petrosino S Cells; 2021 Feb; 10(2):. PubMed ID: 33672574 [TBL] [Abstract][Full Text] [Related]
4. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Petrosino S; Di Marzo V Br J Pharmacol; 2017 Jun; 174(11):1349-1365. PubMed ID: 27539936 [TBL] [Abstract][Full Text] [Related]
5. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. Impellizzeri D; Bruschetta G; Cordaro M; Crupi R; Siracusa R; Esposito E; Cuzzocrea S J Neuroinflammation; 2014 Aug; 11():136. PubMed ID: 25164769 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, Molecular Modeling and Biological Evaluation of Metabolically Stable Analogues of the Endogenous Fatty Acid Amide Palmitoylethanolamide. D'Aloia A; Arrigoni F; Tisi R; Palmioli A; Ceriani M; Artusa V; Airoldi C; Zampella G; Costa B; Cipolla L Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260658 [TBL] [Abstract][Full Text] [Related]
7. A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation. Esposito E; Impellizzeri D; Bruschetta G; Cordaro M; Siracusa R; Gugliandolo E; Crupi R; Cuzzocrea S Eur J Pharmacol; 2016 Jul; 782():107-18. PubMed ID: 27095683 [TBL] [Abstract][Full Text] [Related]
8. Ultramicronized N-palmitoylethanolamine associated with analgesics: Effects against persistent pain. Nobili S; Micheli L; Lucarini E; Toti A; Ghelardini C; Di Cesare Mannelli L Pharmacol Ther; 2024 Jun; 258():108649. PubMed ID: 38615798 [TBL] [Abstract][Full Text] [Related]
9. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Paladini A; Fusco M; Cenacchi T; Schievano C; Piroli A; Varrassi G Pain Physician; 2016 Feb; 19(2):11-24. PubMed ID: 26815246 [TBL] [Abstract][Full Text] [Related]
10. Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats. Mattace Raso G; Santoro A; Russo R; Simeoli R; Paciello O; Di Carlo C; Diano S; Calignano A; Meli R Endocrinology; 2014 Apr; 155(4):1291-301. PubMed ID: 24428531 [TBL] [Abstract][Full Text] [Related]
11. Engineered Esposito G; Pesce M; Seguella L; Lu J; Corpetti C; Del Re A; De Palma FDE; Esposito G; Sanseverino W; Sarnelli G Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799405 [TBL] [Abstract][Full Text] [Related]
12. Ultramicronized palmitoylethanolamide (PEA-um(®)) in the treatment of idiopathic pulmonary fibrosis. Di Paola R; Impellizzeri D; Fusco R; Cordaro M; Siracusa R; Crupi R; Esposito E; Cuzzocrea S Pharmacol Res; 2016 Sep; 111():405-412. PubMed ID: 27402190 [TBL] [Abstract][Full Text] [Related]
13. Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. D'Amico R; Monaco F; Siracusa R; Cordaro M; Fusco R; Peritore AF; Gugliandolo E; Crupi R; Cuzzocrea S; Di Paola R; Impellizzeri D; Genovese T Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768820 [TBL] [Abstract][Full Text] [Related]
14. Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis In Vitro. Cipriano M; Esposito G; Negro L; Capoccia E; Sarnelli G; Scuderi C; De Filippis D; Steardo L; Iuvone T CNS Neurol Disord Drug Targets; 2015; 14(7):828-37. PubMed ID: 25801844 [TBL] [Abstract][Full Text] [Related]
15. The Basal Pharmacology of Palmitoylethanolamide. Rankin L; Fowler CJ Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114698 [TBL] [Abstract][Full Text] [Related]
17. Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. Balvers MG; Verhoeckx KC; Meijerink J; Wortelboer HM; Witkamp RF CNS Neurol Disord Drug Targets; 2013 Feb; 12(1):23-33. PubMed ID: 23394528 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases. Parisi S; Ditto MC; Borrelli R; Fusaro E Minerva Med; 2021 Aug; 112(4):492-499. PubMed ID: 34056884 [TBL] [Abstract][Full Text] [Related]
19. Effect of dietary supplementation with ultramicronized palmitoylethanolamide in maintaining remission in cats with nonflea hypersensitivity dermatitis: a double-blind, multicentre, randomized, placebo-controlled study. Noli C; Della Valle MF; Miolo A; Medori C; Schievano C; Vet Dermatol; 2019 Oct; 30(5):387-e117. PubMed ID: 31237065 [TBL] [Abstract][Full Text] [Related]
20. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Skaper SD; Facci L; Giusti P Mol Neurobiol; 2013 Oct; 48(2):340-52. PubMed ID: 23813098 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]